Lundbeck News and Activities
Presence
Headquarters: Denmark
Lundbeck is a company listed under the stock ticker HLUYY (DK).
Lundbeck has a direct presence in 7 countries.Lundbeck has 6 subsidiaries including Lundbeck Australia, Lundbeck Canada and Lundbeck Germany.
Acquisition, funding and merger involving Lundbeck.
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (posted on October 17 2024).
Executives
View the org chart displaying its 43 main executives
Most searched biographies at Lundbeck
- Charl Van Zyl, President and Chief Executive Officer
- Santiago Arroyo, Director
- Dorothea Wenzel, Chairman of the Board
Popular executive movements at Lundbeck
- Lluís Pujadas Mestres has joined the company as Medical and Regulatory Director, Iberia (posted on May 15 2026).
Create your alert
to follow the executive moves at Lundbeck.
Pharmaceuticals
Lundbeck has 1,911 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).
Popular M&A news in Pharmaceuticals
- GNI has announced the acquisition of Ayumi Pharmaceutical (posted on June 12 2026).
- Parabilis Medicines has just announced a $670 Million fundraising (posted on June 11 2026).
- Chiesi has acquired Kalvista Pharmaceuticals (posted on June 11 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Lundbeck
- Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations
- Lundbeck completes acquisition of Longboard
- Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy
- Efficacy of Vyepti highlighted by new clinical trial results in severe migraine
- Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled
- Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024
- Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth
- Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline
- Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease
- Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery
- View more press releases Close
Social media about Lundbeck
- Lundbeck on Wikipedia, Google News & Yahoo Finance
- Lundbeck on LinkedIn, X (Twitter) & YouTube
